Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laith J Abu-Raddad

Showing results (291-300 of 318) with videos related to

Pageof 32
Sort By:
American Journal of Epidemiology|December 7, 2023
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study designHoussein H Ayoub, Milan Tomy, Hiam Chemaitelly, et al.
Nature Medicine|November 3, 2021
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in QatarPatrick Tang, Mohammad R Hasan, Hiam Chemaitelly, et al.
The Lancet. Infectious Diseases|March 13, 2023
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort studyHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
The Lancet. Microbe|November 14, 2022
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort studyHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
Eclinicalmedicine|August 3, 2023
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational studySuelen H Qassim, Hiam Chemaitelly, Houssein H Ayoub, et al.
Vaccine|April 15, 2024
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradientLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature Communications|June 2, 2022
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in QatarHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
The New England Journal of Medicine|October 6, 2021
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in QatarHiam Chemaitelly, Patrick Tang, Mohammad R Hasan, et al.
Science Advances|October 4, 2023
History of primary-series and booster vaccination and protection against Omicron reinfectionHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Ebiomedicine|July 29, 2023
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational studyHeba N Altarawneh, Hiam Chemaitelly, Houssein H Ayoub, et al.
Pageof 32

Showing results (291-300 of 318) with videos related to

Sort By:
Pageof 32
American Journal of Epidemiology|December 7, 2023
Estimating protection afforded by prior infection in preventing reinfection: applying the test-negative study designHoussein H Ayoub, Milan Tomy, Hiam Chemaitelly, et al.
Nature Medicine|November 3, 2021
BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in QatarPatrick Tang, Mohammad R Hasan, Hiam Chemaitelly, et al.
The Lancet. Infectious Diseases|March 13, 2023
Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort studyHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
The Lancet. Microbe|November 14, 2022
Protection from previous natural infection compared with mRNA vaccination against SARS-CoV-2 infection and severe COVID-19 in Qatar: a retrospective cohort studyHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
Eclinicalmedicine|August 3, 2023
Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational studySuelen H Qassim, Hiam Chemaitelly, Houssein H Ayoub, et al.
Vaccine|April 15, 2024
Effectiveness of two and three doses of COVID-19 mRNA vaccines against infection, symptoms, and severity in the pre-omicron era: A time-dependent gradientLayan Sukik, Hiam Chemaitelly, Houssein H Ayoub, et al.
Nature Communications|June 2, 2022
Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in QatarHiam Chemaitelly, Houssein H Ayoub, Sawsan AlMukdad, et al.
The New England Journal of Medicine|October 6, 2021
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in QatarHiam Chemaitelly, Patrick Tang, Mohammad R Hasan, et al.
Science Advances|October 4, 2023
History of primary-series and booster vaccination and protection against Omicron reinfectionHiam Chemaitelly, Houssein H Ayoub, Patrick Tang, et al.
Ebiomedicine|July 29, 2023
Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational studyHeba N Altarawneh, Hiam Chemaitelly, Houssein H Ayoub, et al.
Pageof 32